We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
- Authors
Luippold, G; Klein, T; Mark, M; Grempler, R
- Abstract
Sodium glucose cotransporter-2 (SGLT-2) is key to reabsorption of glucose in the kidney. SGLT-2 inhibitors are in clinical development for treatment of type 2 diabetes mellitus (T2DM). The mechanism may be of value also in the treatment of type 1 diabetes mellitus (T1DM). This study investigated effects of the SGLT-2 inhibitor, empagliflozin, alone and in combination with insulin, on glucose homeostasis in an animal model of T1DM.
- Publication
Diabetes, obesity & metabolism, 2012, Vol 14, Issue 7, p601
- ISSN
1463-1326
- Publication type
Journal Article
- DOI
10.1111/j.1463-1326.2012.01569.x